Athira Pharma To Focus On Advancement Of ATH-1105 For The Treatment Of Neurodegenerative Diseases, Includes A Reduction In Workforce Of ~70%. Athira Expects One-Time Costs Of ~$2.8M And Cost Savings Of ~$13.4M On An Annualized Basis
Athira Pharma To Focus On Advancement Of ATH-1105 For The Treatment Of Neurodegenerative Diseases, Includes A Reduction In Workforce Of ~70%. Athira Expects One-Time Costs Of ~$2.8M And Cost Savings Of ~$13.4M On An Annualized Basis
In alignment with Athira's focus on continued development of ATH-1105, the Company is implementing cost containment measures including a reduction in workforce of approximately 70%. Athira expects one-time costs of approximately $2.8 million and cost savings of approximately $13.4 million on an annualized basis related to the reduction in the workforce. As a result of these cost containment measures and based on its current operating plan, Athira now expects to extend its cash runway into the first quarter of 2026. Moving forward, the Company will review and consider various options including partnering and financing with the intent of extending its cash runway to achieve initial proof-of-concept and enable further development for ATH-1105 in neurodegenerative diseases.ATH-1105 is an orally delivered, positive modulator of the neurotrophic HGF system that is currently in a Phase 1 clinical trial with completion expected by year end 2024 and commencement of dosing of ALS patients expected in 2025
ATH-1105是一種口服給藥的神經營養因子HGF系統的正調節劑，目前正在進行第一階段的臨床試驗，預計將於2024年底完成，並預計於2025年開始給予ALS患者劑量。
Company announces cost containment measures in alignment with focus on advancing ATH-1105
公司宣佈採取成本控制措施，以推進ATH-1105的發展。
BOTHELL, Wash., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that following the topline data readout from the Phase 2/3 LIFT-AD clinical trial of fosgonimeton to treat Alzheimer's disease (AD) the Company plans to focus on advancing the clinical development program for ATH-1105 as a potential treatment for neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and AD. ATH-1105 is the Company's oral, next-generation small molecule positive modulator of the neurotrophic hepatocyte growth factor (HGF) system currently in development for the treatment of ALS.
華盛頓州Bothell，2024年9月17日（環球新聞社） - Athira Pharma, Inc.（納斯達克：ATHA）是一家臨床階段生物製藥公司，專注於開發小分子化合物來恢復神經細胞健康和減緩神經退行性疾病。今天宣佈，在Phase 2/3 LIFt-AD臨床試驗中，使用fosgonimeton治療阿爾茨海默病（AD）的頭榜數據公佈後，公司計劃專注於推進ATH-1105的臨床開發計劃，作爲治療神經退行性疾病（包括肌萎縮性脊髓側索硬化症（ALS）和AD）的潛在治療方法。ATH-1105是公司的口服、下一代小分子化合物神經營養因子肝細胞生長因子（HGF）系統的正調節劑，目前正在ALS的治療領域開發中。
In alignment with Athira's focus on continued development of ATH-1105, the Company is implementing cost containment measures including a reduction in workforce of approximately 70%. Athira expects one-time costs of approximately $2.8 million and cost savings of approximately $13.4 million on an annualized basis related to the reduction in the workforce. As a result of these cost containment measures and based on its current operating plan, Athira now expects to extend its cash runway into the first quarter of 2026. Moving forward, the Company will review and consider various options including partnering and financing with the intent of extending its cash runway to achieve initial proof-of-concept and enable further development for ATH-1105 in neurodegenerative diseases.
爲了配合Athira繼續開發ATH-1105的重點，該公司正在實施成本控制措施，包括裁員約70%。Athira預計裁員將產生約280萬美元的一次性費用，並在年度基礎上節約約1340萬美元。基於目前的運營計劃，Athira預計現金儲備將延長至2026年第一季度。未來，該公司將審查和考慮各種選擇，包括合作伙伴和融資，以延長現金儲備，實現初步概念驗證並推動ATH-1105在神經退行性疾病領域的進一步發展。
